Giardia vaccination.
Recently, a Giardia vaccine has become commercially available in the USA for prevention of clinical signs of giardiasis and reduction of cyst shedding in dogs and cats. The vaccine is based upon the current state of knowledge of Giardia antigenicity and immunology. Here, Merle Olson, Howard Ceri and Douglas Morck describe studies that led to the development of this vaccine and subsequent efficacy studies. Immunoprophylaxis and immunotherapeutic application of the vaccine are discussed.
Olson
M E
ME
Departments of Microbiology and Infectious Diseases and Biological Sciences, University of Calgary, Alberta, Canada. molson@ucalgary.ca
Ceri
H
H
Morck
D W
DW
D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D000953:Antigens, Protozoan / Q000276:immunology; D002371:Cat Diseases / Q000276:immunology / Q000469:parasitology / Q000517:prevention & control*; D002415:Cats; D004283:Dog Diseases / Q000276:immunology / Q000469:parasitology / Q000517:prevention & control*; D004285:Dogs; D005243:Feces / Q000469:parasitology; D005260:Female; D016829:Giardia lamblia / Q000276:immunology*; D005873:Giardiasis / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D010270:Parasite Egg Count / Q000662:veterinary; D016052:Protozoan Vaccines / Q000276:immunology* / Q000592:standards; D014611:Vaccination / Q000662:veterinary*
D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D016052:Protozoan Vaccines